One very promising approach for the treatment of NAFLD and NASH that has recently emerged is activation of the transcription factor nuclear factor-erythroid 2-related factor 2 (NRF2). Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.